Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 11.90 3,614 01:00:00
Bid Price Offer Price High Price Low Price Open Price
11.30 12.50 11.90 11.90 11.90
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.05 -1.48 -0.54 45
Last Trade Time Trade Type Trade Size Trade Price Currency
13:13:17 O 195,000 12.50 GBX

Eden Research (EDEN) Latest News

More Eden Research News
Eden Research Investors    Eden Research Takeover Rumours

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date Time Title Posts
22/6/202120:24Eden Research9,825
20/5/202110:19Eden Research; novel encapsulation and delivery technologies1,101
07/1/202118:37Eden....Onward and Upwards!-
07/3/201713:47Eden Research- The Natural Solution172
27/2/201611:20Eden Research- The Natural Solution3

Add a New Thread

Eden Research (EDEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Eden Research trades in real-time

Eden Research (EDEN) Top Chat Posts

Eden Research Daily Update: Eden Research Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 11.90p.
Eden Research Plc has a 4 week average price of 11.25p and a 12 week average price of 11.25p.
The 1 year high share price is 20.50p while the 1 year low share price is currently 6.30p.
There are currently 380,340,229 shares in issue and the average daily traded volume is 129,440 shares. The market capitalisation of Eden Research Plc is £45,260,487.25.
investingisatrickygame: Super, Once Eden get US EPA approval for Cedroz and Mevalone, they break new ground in my opinion. Also, with what will then be a self-declared sales pipeline of circa €270 million and the Corteva deal in place, another €40 million self-declared once regulatory approval comes through, Eden will, in my opinion, have reached an inflection point. That point revolves around Company value. The Company will need to revalue, one way or another as the disconnect if we were still at 12p would be so great that it would be worrying. Why is it worrying? Well, in my opinion, the industry clearly knows Eden even though the investment community doesn't. Anyone looking at Eden's regulatory approved and potential future order book could swoop in and placate shareholders with a cheeky bid which I imagine, many would be very happy with. We don't want that, so Eden needs to properly revalue. it is much easier to get true value when starting from a higher, fairer, price point. Once Eden and Corteva's success around seed technology and formulations is understood by everyone, this will open up significant revenue streams for Eden and much industry change in the seed sector, will it not? Again, another trigger for Eden value. Simple maths can be calculated and if we know the average Gross Profit across the business then we can be more accurate on what Eden's earnings per share will be thus ensuring any multiple of EPS will forecast a stronger representation of value for Eden as a company. I continue to believe that will run into £'s per share, even if today that looks like a pipe dream to some and others who wish to criticise based on nothing. Our current commercial contracts in situ and the companies they are with does not justify a terrible share price which is currently 12p.
investingisatrickygame: I'm surprised no one's posted the Eden share price melt score😭
supersonico: Question Time. Despite having a agreement of 27 May 2020 'Update on Bayer Animal Health Agreement' Bayer are not mentioned as Eden partners in Eden 2020 interims 'hTTps://' I have Bayer working with Eden in Crop protection and Parallel with TT. Elanco and Eden are pursuing the 'Next generation development' of Animal Health products. This Half Yearly Report / Sept 2020 'An amendment to the existing licence agreement between Eden and Bayer Animal Health for animal health products was reported in May, for the purposes of progressing the final development of a portfolio of Bayer products based upon Eden's technology and know-how. This amendment involved an increased investment in the project, which was facilitated in part by Eden's successful capital raise in March. Bayer also completed the sale of its animal health business to Elanco, and the relevant agreements have now been transferred to Elanco'. The last sentence is important here as it confirms to me at least the separation of Animal Health and the rest. The paragraph makes no sense if Bayer were only focused on Animal Health. The arrival of the Bayer 7 also tells me all I need to know about Bayer and Eden's continued collaboration. What do you think ??
investingisatrickygame: Spadey Who cares about today! Better to be trending upwards, I agree and some positive, explicit communication would aid that, but Eden has the right product, at the right time and evidently as far as distributors are concerned, at the right price. Also, it has the right profile for Regulators to meet ESG goals. It is also right for the consumer which to be fair, is maybe not understood yet, but hopefully will be. Finally, it is the right profile for funds to invest in and I'm sure and I hope, that Eden and Cenkos will be seriously working on this with existing and new funds, green funds. Sales pipeline Mevalone approved 115 million euros Cedroz approved 59 million euros Corteva Seeds 40 million euros PENDING For sure Eden's annual turnover will rise rapidly now and any fund looking at Eden will look at the sales pipeline, corporate and product profile, the Corteva commercial deal and market sector opportunity and of course, management. With sales coming in and rising rapidly, which I expect them to do, Eden will now tick every box. Oh by the way, the entry price point of 12p is a bargain given the above, so they should be able to mop up a lot of stock on a rising, but relatively low share price and enable some PI's to exit at a profit.
investingisatrickygame: Super, More than anything, I think what we need now is a strong re-iteration of Eden's pipeline and potential business split by A)Mevalone and B) Cedroz. These numbers will be rising in time to account as the new regulatory approvals are granted. I think we should also make it clear to everyone that Cedroz (most likely) means an immediate product sale and so Eden is off and running with each new country approval. We do know that Mevalone is weather dependent and sales with react accordingly. However, with storage apples I assume this variable doesn't apply and if not, sales would occur like Cedroz. This should be clarified to investors too. Eden has to put right the wrong's of last week and that means making sure the investment community understands who Eden are, the problems they are solving and the highly significant relevance and numbers for the regulatory approvals they have had. So aggregated numbers by product, timeline to estimated targets and hoped for sales in 2021 and 2022 to give an indication of hope/expectation whilst also laying down a marker of the reality of sales in Cedroz. As for the Corteva success, Eden told us nothing other than the global market size of seed treatments which means nothing unless Eden intends to satisfy that whole market, which clearly they do not. So, what is the value of the deal; is it still up to €40 million for Europe alone and the same guidance here for timelines, hoped fors etc. My calculation says that if you add the regulatory approvals for the two products and add in Corteva seeds, then Eden's estimated market to satisfy in three years is €214 million. That is HUGE compared to where we are now. Truly transformational. You can take a % of that if you wish, not a problem, still far removed positively from where we are now. If Eden did €10 million of sales in the next 12 months, that is very significant from the last two years performance. Eden needs to showcase this very real possibility of their own numbers and have everyone who knows of views Eden, understand the very real possibilities for Eden as a technology company operation in a global market aiding global agriculture. These are the relevant numbers and messages that need to be communicated so that investors appropriate a more relevant valuation to Eden's share price.
investingisatrickygame: Just for balance and any passive viewers out there, there are revenues immediately and for the coming years. Eden has regulatory approval in various countries for Mevalone and Cedroz with an estimated market and therefore potential annual revenue in due course of €174 million. Thus, it is down to Eastman, Sipcam, Sumi-Agro and a couple of others to go sell it directly to farmers. They will of course, buy stock from Eden to enable those sales purchases to follow through. Eden should make this abundantly clear in their communications so that the market fully understands the potential forward income ahead of them. Broker research papers will take a three-year forward view and clearly this has not been communicated sufficiently. If it had, Eden's share price would not have dropped. That Said, it is up to Eden to get the PI community to understand this fully too and this is not happening and has not been happening for several years. Unfortunately, it is a consistent negative. All of that said, Eden could turn this around in a heartbeat. It just takes a bit of time and consideration to deliver the story properly to the audience you are talking too. The future looks very bright for Eden, but the share price issue does need immediately addressing as it is in my opinion, very, very low in relation to where we are. The only way is up!
kenmitch: Sales,revenues, cash flow and profits are what are needed to get the share price on a sustained run. When will Eden deliver on that? It’s been a VERY long wait. The time to invest for sustained gains, instead of temporary spikes, is when Eden at long last delivers by doing what all successful Companies do. i.e they look to and then DO sell things. I sold again a while ago. Keep watching though. One day perhaps both Eden and Eden posters (who ignore the obvious) WILL get it and sell, and then in quantity. THEN if it ever happens the share price could rocket and fast too.
investingisatrickygame: erinvale1 Do you believe that Eden hasn't sold anything to Eastman as a result of yesterday's approval? I don't. Unfortunately, Eden do not share this information with shareholders/owners which in my opinion they should. Contrast yesterday's significant RNS with this one hxxp:// 1) Signed a partnership agreement (just like Eden) 2) States the reason for product demand (same as Eden) 3) Confirms partner development funding and an upfront payment (same as Eden) However, Fireangel chose to go a step further than Eden and help its shareholders determine and understand the value of the deal. They stated the number of units to be produced, including minimum units and the timeframe for delivering the same, They also stated the value of the agreement and the composition of the revenue they will receive. As a result of that RNS, volume went through the roof and the share price doubled in a day. They are still 50% higher today. Had Eden re-iterated value yesterday of €30.6 million and given a time frame of expectancy to get there and put that in context with last years year-end figures (£1.6 million), coupled with any initial sale agreed I feel certain the share price would have risen much more. They could even have added forecast sales in year 1, why not? Eden needs to be a bit more expansive in sharing news, particularly successful news such as yesterday and if they do, they market will treat them well. However, people don't buy what they don't know and in my opinion, this is an ongoing communication issue for Eden which the market, in-turn, is communicating back to Eden through share price volume and price.
investingisatrickygame: Hello Brucie, I don't think sales should take time to feed through. To my thinking, there should be an order placed by Eastman immediately for the reasons I mentioned. Eden needs good news, so why not mention an initial value in the same way that they do with milestone payments?! IF the investment community doesn't appreciate the value of this deal to Eden, then how can it react appropriately? Equally, this leaves existing shareholders frustrated. And if we haven't mentioned value here, what does that mean when the Corteva RNS comes out? Eden mentioned all prospective values in the Placing RNS, including Corteva. It naturally follows that upon success Eden should re-emphasize these values in the subsequent RNS. Shareholders can then do their own maths if the Company does not do it for them and then make informed investment decisions. However, today's RNS is information incomplete and so it leaves a void. My concern around this is that Eden can continue to deliver value driven success, but the market not recognise it because it has not been spelled out for them. You cannot expect those not currently invested to go back and troll through RNS's hoping to find indicative values of future deals. As the deal is done and regulatory approval given, deal values need to be spelled out. It may not be that Eden will do €30 million in the first year in Italy with Eastman, but it is incumbent of them to re-iterate this value, as they have done before, so that it is there for all to see. No doubt Cenkos will do an update note as a result of today and we will learn their new share price value on Eden.
mirandaj: Mexico approval given for Cedroz in December 2019 - a reminder "Approval of Cedroz in Mexico and access to the US agricultural import market Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce that its commercial partner, Eastman Chemical Company ("Eastman"), has received full authorisation for Eden's nematicide formulation, marketed as Cedroz™ by Eastman, in Mexico. Key highlights of the authorisation: ·    Access now gained into the all-important US agricultural import market ·    Approval is the first for Eden developed products in Mexico and a foothold into the Americas ·    US imports of agricultural products from Mexico totalled $26bn in 2018 ·    Cedroz is formulated with Eden's Sustaineä encapsulation and delivery technology for its improved bioactivity, controlling volatility and advanced crop safety Cedroz is an innovative and natural solution designed to fight nematodes, a pest that is known to cause severe damage to crops globally, in both open field and greenhouse production resulting in yield losses and increasing farmers' costs. Mexico has authorised the use of Cedroz on a wide range of crops, including tomatoes, potatoes, peppers, eggplants, melons, chili peppers, pepinos and squash. The approval in Mexico represents the first for Cedroz, or any Eden-developed product, in the Americas. U.S. imports of agricultural products from Mexico totalled $26 billion in 2018, with Mexico being the largest supplier of agricultural products to the U.S. According to the U.S. Trade Representative, the leading categories of agricultural products from Mexico in 2018 included fresh vegetables ($5.9 billion), with the leading crops including tomatoes and peppers, along with other fresh fruit ($5.8 billion).  Processed fruit and vegetables accounted for another $1.7 billion. As Mexico is a large exporter of fresh produce to the U.S., this is a commercially important territory for Eastman who registered and will distribute Cedroz supplied by Eden. Cedroz offers growers tremendous advantages by providing high levels of efficacy against nematodes.  The active ingredients in Cedroz are exempt from residue limits and have very low or no pre-harvest intervals, giving growers the ability to apply the product just prior to harvest, providing maximum benefits and flexibility.  Cedroz is formulated with Eden's Sustaineä encapsulation and delivery technology, a proven system derived from yeast. Sustaine microcapsules are naturally sourced, plastic-free, biodegradable micro-spheres derived from yeast. The Sustaine technology has enabled the safe and effective use of Eden's registered active ingredients and those of third parties by improving bioactivity, controlling volatility and improving crop safety."
Eden Research share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210622 20:09:14